Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis.

Autor: Villani S; Department of Biomedical, Surgery and Dental Sciences, University of Milan, Milan, Italy., Zanotta N; Institute for Maternal and Child Health-IRCCS 'Burlo Garofolo'-Trieste, Trieste, Italy., Ambrogi F; Department of Clinical Sciences and Community Health, University of Milan, Italy., Comar M; Institute for Maternal and Child Health-IRCCS 'Burlo Garofolo'-Trieste, Trieste, Italy; Medical Science Department, University of Trieste, Trieste, Italy., Franciotta D; Laboratory of Neuroimmunology, National Neurological Institute C. Mondino, Pavia, Italy., Dolci M; Department of Biomedical, Surgery and Dental Sciences, University of Milan, Milan, Italy., Cason C; Institute for Maternal and Child Health-IRCCS 'Burlo Garofolo'-Trieste, Trieste, Italy., Ticozzi R; Department of Biomedical, Surgery and Dental Sciences, University of Milan, Milan, Italy., Ferrante P; Department of Biomedical, Surgery and Dental Sciences, University of Milan, Milan, Italy., Delbue S; Department of Biomedical, Surgery and Dental Sciences, University of Milan, Milan, Italy. Electronic address: serena.delbue@unimi.it.
Jazyk: angličtina
Zdroj: Journal of neuroimmunology [J Neuroimmunol] 2017 Sep 15; Vol. 310, pp. 91-96. Date of Electronic Publication: 2017 Jul 01.
DOI: 10.1016/j.jneuroim.2017.06.012
Abstrakt: Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.
(Copyright © 2017 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: